AbbVie's psoriasis drug Skyrizi beats out Amgen's blockbuster in PhIV head-to-head study
AbbVie’s psoriasis drug Skyrizi beat out Amgen’s Otezla in a Phase IV head-to-head efficacy and safety study testing both treatments in adult patients with moderate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.